Evidence map›Paper›PMID 38470513›Full record

ReviewPurinergic signalling2025

The functional role of P2 purinergic receptors in the progression of gastric cancer.

Fei-Long Zou, Ji-Peng Liu, Cheng Zuo, Peng-Fei He, Jin-Xiong Ye, Wen-Jun Zhang

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Purinergic signalling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Fei-Long ZouThyroid surgery, Shenzhen Bao'an District Songgang People's Hospital, Shenzhen City, 518105, China.
Ji-Peng LiuThe Second Affiliated Hospital, Nanchang University, Nanchang City, Jiangxi Province, 343000, China.
Cheng ZuoThe Second Affiliated Hospital, Nanchang University, Nanchang City, Jiangxi Province, 343000, China.
Peng-Fei HeThe Second Affiliated Hospital, Nanchang University, Nanchang City, Jiangxi Province, 343000, China.
Jin-Xiong YeThyroid surgery, Shenzhen Bao'an District Songgang People's Hospital, Shenzhen City, 518105, China. 490615456@qq.com.
Wen-Jun ZhangThe Second Affiliated Hospital, Nanchang University, Nanchang City, Jiangxi Province, 343000, China. ndefy22057@ncu.edu.cn.
Nanchang University · CNHegang People's Hospital · CNShenzhen Bao'an District People's Hospital · CN

Funding

Project of Education Department of Jiangxi Province GJJ2200238
6 · The paper itself

Abstract

Studies have confirmed that P2 purinergic receptors (P2X receptors and P2Y receptors) expressed in gastric cancer (GC) cells and GC tissues and correlates with their function. Endogenous nucleotides including ATP, ADP, UTP, and UDP, as P2 purinergic receptors activators, participate in P2 purinergic signal transduction pathway. These activated P2 purinergic receptors regulate the progression of GC mainly by mediating ion channels and intracellular signal cascades. It is worth noting that there is a difference in the expression of P2 purinergic receptors in GC, which may play different roles in the progression of GC as a tumor promoting factor or a tumor suppressor factor. Among them, P2 × 7, P2Y2 and P2Y6 receptors have certain clinical significance in patients with GC and may be used as biological molecular markers for the prediction of patients with GC. Therefore, in this paper, we discuss the functional role of nucleotide / P2 purinergic receptors signal axis in regulating the progression of GC and that these P2 purinergic receptors may be used as potential molecular targets for the prevention and treatment of GC.

Indexed as

Receptors, Purinergic P2Stomach NeoplasmsAnimalsDisease ProgressionHumansSignal TransductionReceptors, Purinergic P2GCP2X receptorsP2Y receptorsTreatment

Identifiers

PMID38470513
PMCPMC12454698
OpenAlexW4392715031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.